{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:32:14Z","timestamp":1761093134572,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.urolonc.2020.11.026","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T09:30:12Z","timestamp":1607419812000},"page":"136.e11-136.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Surveillance of postchemotherapy subcentimeter residual retroperitoneal mass in metastatic nonseminomatous germ cell tumor: Does how you measure matter?"],"prefix":"10.1016","volume":"39","author":[{"given":"Cody E.","family":"Cotner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"Surveillance, epidemiology, and end results cancer statistics review, 1975 - 2016","author":"Howlader","key":"10.1016\/j.urolonc.2020.11.026_bib0001"},{"issue":"5","key":"10.1016\/j.urolonc.2020.11.026_bib0002","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1158\/1055-9965.EPI-10-0031","article-title":"International trends in the incidence of testicular cancer, 1973 \u2013 2002","volume":"19","author":"Chia","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"10.1016\/j.urolonc.2020.11.026_bib0003","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<852::AID-IJC30>3.0.CO;2-S","article-title":"Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (NSGCT)","volume":"83","author":"Kuczyk","year":"1999","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2020.11.026_bib0004","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2015.07.044","article-title":"Guidelines on testicular cancer: 2015 update","volume":"68","author":"Albers","year":"2015","journal-title":"Eur Urol"},{"issue":"Suppl 6","key":"10.1016\/j.urolonc.2020.11.026_bib0005","doi-asserted-by":"crossref","first-page":"vi125","DOI":"10.1093\/annonc\/mdt304","article-title":"Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Oldenburg","year":"2013","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2020.11.026_bib0006","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/cncr.22181","article-title":"Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?","volume":"107","author":"Spiess","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2020.11.026_bib0007","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.1995.13.5.1177","article-title":"Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups","volume":"13","author":"Steyerberg","year":"1995","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.11.026_bib0008","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.urolonc.2011.05.018","article-title":"The management of subcentimeter residual mass in NSGCT: pcRPLND vs. observation","volume":"29","author":"Daneshmand","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2020.11.026_bib0009","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2020.11.026_bib0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/JCO.2009.23.0714","article-title":"Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?","volume":"28","author":"Ehrlich","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.11.026_bib0011","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2009.23.0755","article-title":"Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery","volume":"28","author":"Kollmannsberger","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.11.026_bib0012","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/annonc\/mdt425","article-title":"A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor","volume":"25","author":"Ravi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2020.11.026_bib0013","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1200\/JCO.1992.10.4.569","article-title":"Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?","volume":"10","author":"Fossa","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.11.026_bib0014","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1331::AID-CNCR16>3.0.CO;2-I","article-title":"Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer: a decision analysis","volume":"85","author":"Steyerberg","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2020.11.026_bib0015","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1200\/JCO.2003.03.184","article-title":"Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses","volume":"21","author":"Oldenburg","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.11.026_bib0016","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0022-5347(18)31071-1","article-title":"High rate of retroperitoneal teratoma despite complete remission after chemotherapy for metastatic nonseminomatous germ cell tumor","volume":"177","author":"Steiner","year":"2007","journal-title":"J Urol"},{"issue":"7S","key":"10.1016\/j.urolonc.2020.11.026_bib0017","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1200\/jco.2011.29.7_suppl.224","article-title":"Pathohistologic findings in patients with nonseminomatous germ cell tumors (NSGCT) who undergo postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for small tumors","volume":"29","author":"Pfister","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.11.026_bib0018","unstructured":"Karellas M, Carver BS, Stasi J, et al. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection for men with cII non-seminomatous germ cell tumors and a radiographically normal retroperitoneum."},{"issue":"3 Pt 2","key":"10.1016\/j.urolonc.2020.11.026_bib0019","first-page":"976","article-title":"Complications of post-chemotherapy retroperitoneal lymph node dissection","volume":"153","author":"Baniel","year":"1995","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.11.026_bib0020","first-page":"368","article-title":"Early and late complications of retroperitoneal lymphadenectomy in testis cancer","volume":"34","author":"Jewett","year":"1991","journal-title":"Can J Surg"},{"issue":"5","key":"10.1016\/j.urolonc.2020.11.026_bib0021","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.urolonc.2008.10.026","article-title":"Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer","volume":"28","author":"Subramanian","year":"2010","journal-title":"Urol Oncol"},{"issue":"7S","key":"10.1016\/j.urolonc.2020.11.026_bib0022","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1200\/JCO.2019.37.7_suppl.524","article-title":"Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with testis cancer in the salvage setting","volume":"37","author":"Albers","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.11.026_bib0023","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/14737140.2019.1580146","article-title":"Management of residual masses in testicular germ cell tumors","volume":"19","author":"Heidenreich","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.1016\/j.urolonc.2020.11.026_bib0024","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.eururo.2006.06.047","article-title":"Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients","volume":"51","author":"Vergouwe","year":"2007","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.11.026_bib0025","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2007.12.025","article-title":"European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II","volume":"53","author":"Krege","year":"2008","journal-title":"Eur Urol"},{"issue":"S4","key":"10.1016\/j.urolonc.2020.11.026_bib0026","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/annonc\/mdp139","article-title":"Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Schmoll","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392030613X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392030613X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:19:26Z","timestamp":1761041966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392030613X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S107814392030613X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.11.026","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surveillance of postchemotherapy subcentimeter residual retroperitoneal mass in metastatic nonseminomatous germ cell tumor: Does how you measure matter?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}